TEVA PHARMACEUTICALS USA, INC. for TEVA PHARMACEUTICALS USA INC
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 20, 2018 | $1,130,000 | Replaced |
| 2nd Quarter - Amendment | Jul 24, 2018 | $1,150,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act"; HR 2051-FAST Generics Act; S.771-Improving Access to Affordable Drugs Act; HR 749-Lower Drugs Through Competition Act; Administration review of drug pricing policies; and proposals relating to drug importation policy.
Foreign entity interest: Teva Pharmaceutical Industries, Ltd., as the indirect parent of Teva Pharmaceuticals USA Inc., has an interest in the issues listed.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES M. FENTON | — |
| DOLLY A JUDGE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.